Baseline data (T0) on fluticasone and placebo groups
| Parameter | Fluticasone | Placebo | |||||
|---|---|---|---|---|---|---|---|
| Median | Range | Median | Range | ||||
| FEV1(litres) | 2.49 | 1.69–4.86 | 2.69 | 1.77–4.26 | |||
| ΔFEV1 (%) | 24 | 12–80 | 22 | 5–76 | |||
| FEV1/FVC % | 67 | 43–77 | 65 | 40–84 | |||
| FEF25–75(litres) | 1.33 | 0.72–3.93 | 1.91 | 0.62–3.89 | |||
| PC20FEV1(mg) | 0.19 | 0.03–1.74 | 0.11 | 0.03–8 | |||
| T cells (no./104μm2) | 6.3 | 4.1–14.4 | 5.2 | 3.8–17.3 | |||
| Primed T cells (no./104μm2) | 4.9 | 3.1–12.5 | 4.3 | 2.7–13.6 | |||
| CD4:CD8 ratio | 2.8 | 0.5–5.5 | 2.15 | 0.7–4.0 | |||
| CD68+ cells (no./104μm2) | 4.12 | 2.3–11.2 | 3.7 | 1.9–12.5 | |||
| D1+MQ subset (%)2-151 | 33 | 6–55 | 35 | 15–46 | |||
| D7+MQ subset (%) | 46 | 23–68 | 47 | 33–60 | |||
| D1+/D7+MQ subset (%) | 20.5 | 8–33 | 20.5 | 14–26 | |||
| Eosinophils (no./104μm2) | 1.7 | 0.5–2.4 | 1.25 | 0.05–2.2 | |||
| Activated eosinophils (no./104μm2) | 1.5 | 0.05–1.9 | 0.45 | 0.05–1.88 | |||
↵2-151 Percentage of total stained cells showing specific phenotype.